1Harris, M & Zimmet, P (1997) Classification of diabetes mellitus and other categories of glucose intolerance. In International Textbook of Diabetes Mellitus, 2nd ed., pp. 9–23 [, editors]. Chichester: John Wiley and Sons Limited.
2Barr, AJ, Ugochukwu, E, Lee, WH, et al. (2009) Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136, 352–363.
3Valentino, L & Pierre, J (2006) JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71, 713–721.
4Tonks, NK, Diltz, CD & Fischer, EH (1988) Purification of the major protein-tyrosine-phosphatases of human placenta. J Biol Chem 263, 6722–6730.
5Goldstein, BJ (2002) Protein-tyrosine phosphatase 1B (PTP1B): emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J Clin Endocr Metab 87, 2474–2480.
6Seely, BL, Staubs, PA, Reichart, DR, et al. (1996) Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes 45, 1379–1385.
7Zabolotny, JM, Haj, FG, Kim, YB, et al. (2004) Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem 279, 24844–24851.
8Cromlish, WA, Tang, M, Kyskan, R, et al. (2006) PTP1B-dependent insulin receptor phosphorylation/residency in the endocytic recycling compartment of CHO-IR cells. Biochem Pharmacol 72, 1279–1292.
9Asante-Appiah, E & Kennedy, BP (2003) Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am J Physiol Endocrinol Metab 284, E663–E670.
10Saltiel, AR (1996) Diverse signaling pathways in the cellular actions of insulin. Am J Physiol Endocrinol Metab 270, E375–E385.
11Ahmad, F, Azevedo, JJ, Cortright, R, et al. (1997) Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest 100, 449–458.
12Elchebly, M, Payette, P, Michaliszyn, E, et al. (1999) Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544–1548.
13Escriva, F, Rodriguez, AG, Millan, EF, et al. (2010) PTP1B deficiency enhances liver growth during suckling by increasing the expression of insulin-like growth factor-I. J Cell Physiol 225, 214–222.
14Van Huijsduijnen, RH, Bombrun, A & Swinnen, D (2002) Selecting protein tyrosine phosphatases as drug targets. Drug Discov Today 7, 1013–1019.
15Park, H, Bhattarai, BR, Ham, SW, et al. (2009) Structure-based virtual screening approach to identify novel classes of PTP1B inhibitors. Eur J Med Chem 44, 3280–3284.
16Combs, AP (2010) Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J Med Chem 53, 2333–2344.
17Wasser, SP & Weis, AL (1999) Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 19, 65–96.
18Wasser, SP (2011) Current findings, future trends, and unsolved problems in studies of medicinal mushrooms. Appl Microbiol Biotechnol 89, 1323–1332.
19Seto, SW, Lam, TY, Tam, HL, et al. (2009) Novel hypoglycemic effects of Ganoderma lucidum water-extracct in obese/diabetic (+ db/+db) mice. Phytomedicine 16, 426–436.
20Meng, GL, Zhu, HY, Yang, SL, et al. (2011) Attenuating effects of Ganoderma lucidum polysaccharides on myocardial collagen cross-linking relates to advanced glycation end product and antioxidant enzymes in high-fat-diet and streptozotocin-induced diabetic rats. Carbohydr Polym 84, 180–185.
21Yang, BK, Jeong, SC, Park, JB, et al. (2001) Swimming endurance capacity of mice after administration of exo-polymer produced from submerged mycelia culture of Ganoderma lucidum. J Microbiol Biotechn 11, 902–905.
22Hikino, H & Mizuno, T (1989) Hypoglycemic actions of some heteroglycans of Ganoderma lucidum fruit bodies. Planta Med 55, 385–385.
23Wachtel-Galor, S, Tomlinson, B & Benzie, IFF (2004) Ganoderma lucidum (‘Lingzhi’), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Brit J Nutr 91, 263–269.
24Teng, BS, Wang, CD, Yang, HJ, et al. (2011) A protein tyrosine phosphatase 1B activity inhibitor from the fruiting bodies of Ganoderma lucidum (Fr.) Karst and its hypoglycemic potency on streptozotocin-induced type 2 diabetic mice. J Agr Food Chem 59, 6492–6500.
25Kobayashi, K, Forte, TM, Taniguchi, S, et al. (2000) The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism 49, 22–31.
26Kodama, H, Fujita, M & Yamaguchi, I (1994) Development of hyperglycaemia and insulin resistance in conscious genetically diabetic (C57BL/KsJ-db/db) mice. Diabetologia 37, 739–744.
27Folch, J, Lees, M & Sloane Stanley, GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226, 497–509.
28Chernoff, J, Schievella, AR, Jost, CA, et al. (1990) Cloning of a cDNA for a major human protein-tyrosine-phosphatase. Proc Natl Acad Sci U S A 87, 2735–2739.
29Bialy, L & Waldmann, H (2005) Inhibitors of protein tyrosine phosphatases: next-generation drugs? Angew Chen Int Ed Engl 44, 3814–3839.
30Seiner, DR, Labutti, JN & Gates, KS (2007) Kinetics and mechanism of protein tyrosine phosphatase 1B inactivation by acrolein. Chem Res Toxicol 20, 1315–1320.
31Liu, DG, Gao, Y, Voigt, JH, et al. (2003) Acylsulfonamide-containing PTP1B inhibitors designed to mimic an enzyme-bond water of hydration. Bioorg Med Chem Lett 13, 3005–3007.
32Liu, GX, Tan, JZ, Niu, CY, et al. (2006) Molecular dynamics stimulations of interaction between protein-tyrosine phosphatase 1B and a bidentate inhibitor. Acta Pharmacol Sin 27, 100–110.
33Asante-Appiah, E, Patel, S, Dufresne, C, et al. (2002) The structure of PTP1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates. Biochemistry 41, 9043–9051.
34Bartlett, AH & Park, PW (2010) Proteoglycans in host–pathogen interactions: molecular mechanism and therapeutic implications. Exp Rev Mol Med 12, 1–22.
35Bach-Knudsen, KE & Jørgensen, H (2007) Impact of wheat and oat polysaccharides provided as rolls on the digestion and absorption processes in the small intestine of pigs. J Sci Food Agr 87, 2399–2408.
36Liu, G, Xin, ZL, Liang, H, et al. (2003) Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. J Med Chem 46, 3437–3440.
37Glover, NR & Tracey, AS (1999) Modeling studies of the interaction between the insulin receptor kinase domain and protein tyrosine phosphatase 1B. J Am Chem Soc 121, 3579–3589.
38Glover, NR & Tracey, AS (1999) Nuclear magnetic resonance and restrained molecular dynamics studies of the interaction of an epidermal growth factor-derived peptide with protein tyrosine phosphatase 1B. Biochemistry 38, 5256–5271.
39Tagami, S, Sakaue, S, Honda, T, et al. (2002) Effects of troglitazone on skeletal muscle and liver protein tyrosine phosphatase activity in insulin-resistant Otsuka Long-Evans Tokushima fatty rats. Curr Ther Res 63, 572–586.
40Tagami, S, Honda, T, Yoshimura, H, et al. (2002) Triglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima fatty rats. Tohoku J Exp Med 197, 169–181.
41Haj, F, Zabolotny, JM, Kim, Y, et al. (2006) Liver-specific protein tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B− / − mice. J Biol Chem 280, 15038–15046.
42Fukuda, S, Ohta, T, Sakata, S, et al. (2010) Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551. Diabetes Obes Metab 12, 299–306.
43Wang, ZQ, Ribnicky, D, Zhang, XH, et al. (2011) An extract of Artemisia dracunculus L. enhances insulin receptor signaling and modulates gene expression in skeletal muscle in KK-Ay mice. J Nutr Biochem 22, 71–78.
44Mao, XQ, Yu, F, Wang, N, et al. (2009) Hypoglycemic effect of polysaccharide enriched extract of Astragalus membranaceus in diet induced insulin resistant C57BL/6J mice and its potential mechanism. Phytomedicine 16, 416–425.
45Wu, Y, Ou-Yang, JP, Wu, K, et al. (2005) Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B. Acta Pharmacol Sin 26, 345–352.
46Bosch, F, Pujol, A & Valera, A (1998) Transgenic mice in the analysis of metabolic regulation. Annu Rev Nutr 18, 207–232.
47Kim, MK, Chae, YN, Son, MH, et al. (2008) PAR-5359, a well-banlanced PPARα/β dual agonist, exhibits equivalent antidiabetic and hypolidemic activities in vitro and in vivo. Eur J Pharmacol 595, 119–125.
48Bhavsar, SK, Singh, S, Giri, S, et al. (2009) Effect of saponins from Helicteres isora on lipid and glucose metabolism regulating genes expression. J Ethnopharmacol 124, 426–433.
49Matveyenko, AV, Dry, S, Cox, HI, et al. (2009) Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes interactions with metformin. Diabetes 58, 1604–1615.
50Bhattarai, BR, Ko, JH, Shrestha, S, et al. (2007) Inhibition of IKK-β: a new development in the mechanism of the anti-obesity effects of PTP1B inhibitors SA18 and SA32. Bioorg Med Chem 20, 1075–1077.
51Garber, AJ (2002) Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. Diabetes Obes Metab 4, S5–S12.
52Tao, R, Ye, F, He, YB, et al. (2009) Improvement of high-fat-diet-induced metabolic syndrome by a compound from Balanophora polyandra Griff in mice. Eur J Pharmacol 616, 328–333.
53Yamabe, N, Noh, JS, Park, CH, et al. (2010) Evaluation of lognan, iridoid glycoside from Corni fructus, on hepatic and renal glucolipotoxicity and inflammation in type 2 diabetic db/db mice. Eur J Pharmacol 648, 179–187.
54Gum, RJ, Gaede, LL, Koterski, SL, et al. (2003) Redution of protein phosphatase 1B increase insulin-dependent signaling in ob/ob mice. Diabetes 52, 21–28.